Summary
The numbers of deaths caused by HIV could increase substantially if the COVID-19 epidemic leads to interruptions in the availability of HIV services. We compare publicly available scenarios for COVID-19 mortality with predicted additional HIV-related mortality based on assumptions about possible interruptions in HIV programs. An interruption in the supply of ART for 40% of those on ART for 3 months could cause a number of deaths on the same order of magnitude as the number that are anticipated to be saved from COVID-19 through social distancing measures. In contrast, if the disruption can be managed such that the supply and usage of ART is maintained, the increase in AIDS deaths would be limited to 1% over five years, although this could still be accompanied by substantial increases in new HIV infections if there are reductions in VMMC, oral PrEP use, and condom availability.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: BLJ has received research grants from the Bill and Melinda Gates Foundation for the submitted work; and personal fees from Kaiser Permanente outside the submitted work. JAS has received research grants from the Bill and Melinda Gates Foundation for the submitted work; and personal fees from BMGF outside the submitted work. TBH has received research grants from the Bill and Melinda Gates Foundation and MRC for the submitted work; grants from BMGF, MRC and NIH outside the submitted work; and personal fees from WHO, Global Fund and BMGF outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work was supported by the Bill & Melinda Gates Foundation [OPP1194416]. We also acknowledge funding from MRC GIDA [MR/R015600/1]; this award is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
b.jewell{at}imperial.ac.uk; jennifer.smith{at}imperial.ac.uk; timothy.hallett{at}imperial.ac.uk
Data Availability
There are no data referred to in this study beyond those that are cited.
